Primary tabs

Drug and antibiotic resistance, considered a bane in the scientific and developing world, has affected our communities and society as a whole. In fact, this phenomenon is hazardous, not just to the current generation’s immunity but also affects their offspring. According to the CDC, as of 2013, 2 million Americans each year are found to be invulnerable to antibiotics, with more than 20,000 dying from infections caused by resistant bacteria. Therefore, treating recurring illnesses has become more and more challenging, due to the pathogen’s ability to multiply prolifically, resulting in the therapy itself being rendered ineffectual.

Now, a new more robust, 25,000 times more potent version of the antibiotic vancomycin (v3) has been introduced. Unlike its ancestors, this has a ‘three-pronged’ method that acts to kill the otherwise unsusceptible or evolved bacteria.



What Resistant Means

Vancomycin, commonly used in tackling life-threatening gram positive bacterial infections caused by streptococci, staphylococci and enterococci, prevents the microorganisms from building cell walls by binding to the peptides necessary for building this structure. Previously, the antibiotic connected to the amino acid D-alanine (D-ala) but now mutant strains of the bacteria possess the D-lactic (D-lac) making it hard for the drug to bind and eliminate the mutant strain.

Creating the New Antibiotic

Scientists took upon this issue to find a solution for the resistant bacteria that contained protein fragments ending with D-lac. They developed and re-developed vancomycin using techniques like cell construction and cell death to stop the bacteria from proliferating.

Staphylococcus aureus, one of the main drug-resistant culprits. Image credits: CDC/ Matthew J. Arduino, DRPH

In 2011, Dale Boger and his team, at California’s Scripps Research Institute, started creating various versions of the “last resort” antibiotic based on previous work. Earlier this year, they hit the nail on the head by making a three-part (using three different, independent mechanisms in one), all-powerful super-drug that is believed to be 25,000 times more effective than the previous variants of vancomycin. While testing the prototype, it was subject to VRE (vancomycin resistant enterococci) and VRSA (vancomycin resistant staphylococcus aureus) microbes, where even after continuous rounds of exposure, the bacteria did not survive. It was established that such superiorly designed antibiotics were not prone to antimicrobial activity and devoid of clinical resistance.

The group published this study in Proceedings of the National Academy of Sciences of the United States of America titled ‘Peripheral modifications of [Ψ[CH2NH]Tpg4] vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics.’

Future of Antibiotic Research

Praise for this advancement in medicine, after much trial and error, was indeed well-deserved. Chemist at Yale University, Scott Miller, said, “This is pretty special. It’s really the culmination of a decades-long effort.” He goes on to mention that this kind of novel design, specifically targeting the weak spots of immune bacteria in more ways than one, is an important tool in creating new compounds in the future. Also, co-creator, Borger was quoted saying, these types of drugs could “overcome the forces of evolution and selection responsible for bacterial resistance, that are less prone or even impervious to resistance development, that avoid many of the common mechanisms of resistance, and that are more durable than ever before.”

Although still not ready for human use, the new vancomycin is indicated to be a stronger last line of defense and stable in composition, which hopefully motivates researchers to generate more of them in the fight against bacterial infection and antibiotic resistance.

Top image: New antibiotic offers a potent weapon against antibiotic-resistant infections. U.S. Centers for Disease Control and Prevention - Medical Illustrato


Service, R. (2017), AAAS,, (accessed 4 June 2017)

Andrei, M. (2017), ZME Science,, (accessed 4 June 2017)

West Side Story (2017), TWS,, (accessed 5 June 2017)

Centers for Disease Control & Prevention (2013),, (accessed 5 June 2017)

Okano, A. et al.(2017), PNAS, ’Peripheral modifications of [Ψ[CH2NH]Tpg4] vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics.’

Meghna's picture

Meghna Rao, MSc

A postgraduate in Bioscience with work experience in research and communications in the fields of science, health and medicine. Her specializations include writing and developing scientific material for websites, blogs, and other print and digital media, content curation and management, and medical proofreading and editing. She also has a fair knowledge in marketing communications and science journalism. Also, Meghna is passionate about yoga, working with non-profits and travel blogging. Read More

No comment

Leave a Response